Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitors plus standard therapy after endovascular treatment for acute ischemic stroke
ChiCTR2500104176Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab and alirocumab in ischemic stroke (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Proportion of patients with modified Rankin Scale score 0 to 2 at 90 days. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
evolocumabalirocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500104176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104176.